US Broker Ratings

Relay Therapeutics, Inc. (RLAY) Stock Analysis: Exploring a 68.79% Potential Upside for Investors

Relay Therapeutics, Inc. (NASDAQ: RLAY), a clinical-stage biotechnology company, is making waves in the healthcare sector with its innovative approach to drug discovery, particularly in targeted..

Theravance Biopharma, Inc. (TBPH) Stock Analysis: Exploring a 42.63% Potential Upside in the Biotech Sector

For investors seeking a promising opportunity in the biotechnology sector, Theravance Biopharma, Inc. (NASDAQ: TBPH) presents a compelling case with a potential upside of 42.63%. With..

Cullinan Therapeutics, Inc. (CGEM) Investor Outlook: Potential Upside of 183.41% and Strong Buy Ratings

Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is capturing investor attention with a remarkable potential upside of 183.41% as reflected in its current analyst ratings. The company’s focus..

Fulgent Genetics (FLGT) Investor Outlook: Exploring 24.65% Potential Upside in the Diagnostics Sector

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the healthcare sector, particularly in the diagnostics and research industry, is capturing investor attention with its innovative..

CareDx, Inc. (CDNA) Stock Analysis: Exploring a 16.57% Potential Upside in the Healthcare Sector

Investors with an eye on the healthcare sector may find CareDx, Inc. (NASDAQ: CDNA) a compelling prospect. Specializing in diagnostic solutions for transplant patients, CareDx is..

Tilray Brands, Inc. (TLRY) Stock Analysis: Can 59% Upside Drive Investor Interest?

As the cannabis industry continues to evolve and mature, Tilray Brands, Inc. (NASDAQ: TLRY) stands as a prominent player navigating the complex global landscape of medical..

Kura Oncology, Inc. (KURA) Stock Analysis: Biotech Innovator with a 198% Upside Potential

Kura Oncology, Inc. (NASDAQ: KURA) is making waves within the biotechnology sector, capturing investor attention with its promising pipeline and compelling upside potential. With a market..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: A Biotech with an 80.50% Upside Potential

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is capturing the attention of investors with its significant upside potential in the biotechnology sector. This clinical-stage biopharmaceutical company, based in..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Healthcare Innovator with 139% Potential Upside

Niagen Bioscience, Inc. (NAGE), a burgeoning player in the biotechnology sector, has recently captured the attention of investors with its substantial growth prospects. Based in the..

Mind Medicine (MNMD) Stock Analysis: An Investor’s Look at 113% Potential Upside

Mind Medicine (MindMed) Inc. (MNMD) is capturing the attention of investors with its impressive potential upside of 113.45%, according to recent analyst ratings. As a pioneering..

Tectonic Therapeutic, Inc. (TECX): Investor Outlook with a Potential 261% Upside

Tectonic Therapeutic, Inc. (NASDAQ: TECX), a promising player in the biotechnology sector, is capturing investor attention with its innovative approach to targeting G protein-coupled receptors (GPCRs)...

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Promising 26.73% Upside in the Biotech Sector

Tyra Biosciences, Inc. (NASDAQ: TYRA) is capturing the attention of investors with its potential for significant growth in the healthcare sector. As a clinical-stage biotechnology company,..

AnaptysBio, Inc. (ANAB) Stock Analysis: 30% Upside Potential with Strong Analyst Support

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company, has been capturing investor attention with its impressive growth metrics and a substantial potential upside. Based in San..

REGENXBIO Inc. (RGNX) Stock Analysis: Exploring the 110% Potential Upside and Strategic Growth in Gene Therapy

REGENXBIO Inc. (RGNX), a pioneering player in the biotechnology sector, has been capturing attention with its innovative approach to gene therapy. Based in Rockville, Maryland, this..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Unpacking a Potential 82.5% Upside in Gene Therapy Innovation

For investors looking to capitalize on the burgeoning field of biotechnology, Taysha Gene Therapies, Inc. (TSHA) presents an intriguing opportunity. This Dallas-based company, with a market..

uniQure N.V. (QURE) Stock Analysis: Exploring a 120.75% Potential Upside in Gene Therapy Innovation

uniQure N.V. (NASDAQ: QURE), a Dutch biotechnology company, emerges as a noteworthy player in the healthcare sector, focusing on pioneering gene therapies for rare and severe..

Immatics N.V. (IMTX) Stock Analysis: Riding the Biotechnology Wave with an 80.81% Potential Upside

German biopharmaceutical company Immatics N.V. (NASDAQ: IMTX) is making waves in the biotechnology sector with its cutting-edge approach to cancer treatment. At the heart of the..

Community Health Systems, Inc. (CYH) Stock Analysis: Unpacking a 21.72% Potential Upside Amidst Healthcare Volatility

Community Health Systems, Inc. (NYSE: CYH) presents a complex yet intriguing opportunity for investors looking to tap into the healthcare sector. With its operations deeply embedded..

Claritev Corporation (CTEV) Stock Analysis: A 99% Upside Beckons as Analysts Rally Behind Healthcare Innovator

Claritev Corporation (CTEV) is capturing the attention of investors with its robust potential for growth, particularly in the burgeoning sector of healthcare information services. Headquartered in..

Capricor Therapeutics, Inc. (CAPR) Stock Analysis: Exploring a 71% Upside Potential in Biotechnology

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is drawing significant attention in the biotechnology sector, not just for its ambitious therapeutic developments but also for its remarkable potential..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds